EFFECT OF CABERGOLINE ON GLUCOSE TOLERANCE AND WEIGHT IN PATIENTS WITH OBESITY.

Introduction: Global obesity rates are rising due to rapid urbanisation and sedentary lifestyles, affecting health and economics. Modifications to one's way of life, medical interventions, and surgical procedures are among the methods that can be utilised to manage obesity. New dopaminergic drugs show promise, but regulatory hurdles remain. Dopamine modulation may reduce metabolic dysfunctions, but more research is needed. Aim and objectives: This study aims to examine the impact of Cabergoline on glucose tolerance and weight in obese adults. Method: The impact of cabergoline on blood glucose levels was examined in a double-blind research including 120 obese patients who were given either the active ingredient or a placebo. There was no statistically significant difference seen between the groups (P = 0.792). Medications were delivered every week for 3 months in addition to the ongoing therapy. The study involved the implementation of fundamental laboratory tests and measures to continuously monitor the outcomes. Result: This study presents the initial characteristics of the Cabergoline and Control groups, and compares them at 3 and 6 months. There were no notable disparities observed in terms of weight, waist circumference, blood pressure, or BMI. Once more, it examines the laboratory attributes before and following a 3-month therapy period, revealing that there are no notable disparities between the Cabergoline and Control groups in the majority of measures. Conclusion: Cabergoline did not differ significantly from the control group in terms of weight, waist circumference, blood pressure, body mass index (BMI), or the majority of laboratory values after three months. [ABSTRACT FROM AUTHOR]